Caladrius Biosciences to Participate at Upcoming December Conferences
December 02 2019 - 4:05PM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company pioneering advancements of cell therapies in select
cardiovascular and autoimmune diseases, announced today that the
Company will present at the following conferences in December:
16th Cardio Vascular Clinical Trialists
Forum
|
Date & Time: |
Thursday, December 5, 2019 at 3:30pm (ET) |
| Presenter: |
Douglas W. Losordo, M.D., FACC,
FAHA, Chief Medical Officer at Caladrius Biosciences |
| Location: |
Embassy of France in Washington
D.C. |
BioNJ’s Cybersecurity Awareness Breakfast
Briefing
|
Date & Time: |
Thursday, December 12, 2019 at 8:30am (ET) |
| Presenter: |
Greg Berkin, MSc, Vice President
of IT and Cybersecurity and Chief Information Officer at Caladrius
Biosciences |
| Location: |
Princeton Innovation Center
BioLabs in Princeton, NJ |
About Caladrius BiosciencesCaladrius is a
late-stage therapeutics development biopharmaceutical company
pioneering advancements of cell therapies for select cardiovascular
and autoimmune diseases. Our leadership team collectively has
decades of biopharmaceutical development experience and
world-recognized scientific achievement in the fields of
cardiovascular and autoimmune disease, among other areas. Our
current product candidates include three developmental treatments
for cardiovascular diseases based on our CD34+ cell therapy
platform: CLBS12, recipient of a SAKIGAKE designation in Japan and
advanced therapy medicinal product classification (ATMP) in Europe,
eligible for early conditional approval for the treatment of
critical limb ischemia in Japan based on an ongoing clinical trial;
CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial
in the U.S.A. for the treatment of coronary microvascular
dysfunction; and CLBS14, a Phase 3 ready clinical program in no
option refractory disabling angina and recipient of a RMAT
designation in the U.S.A. For more information on the company,
please visit www.caladrius.com
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024
